Veracyte, Inc. (VCYT) vs Xenon Pharmaceuticals Inc. (XENE)

A side-by-side comparison of Veracyte, Inc. and Xenon Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Veracyte, Inc. logo
VCYT
Veracyte, Inc.
$3.56B
$44.65HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Xenon Pharmaceuticals Inc. logo
XENE
Xenon Pharmaceuticals Inc.
$3.54B
$36.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — VCYT vs XENE

growth of $100 · dividends reinvested · last 10y
VCYT +521.5% (+20.0%/yr)XENE +355.4% (+16.4%/yr)VCYT compounded faster over this window
02004006008001kStart $10020182020202220242026$622$455
VCYT XENE

VCYT vs XENE: by the numbers

  • •VCYT is the larger company ($3.56B vs $3.54B market cap).
  • •VCYT is profitable (20.37% net margin) while XENE runs a net loss (-4612.13%).

Metrics side by side

Valuation

MetricVCYTXENE
P/E ratio31.89N/A
Forward P/E23.33N/A
P/S ratio6.34N/A
P/B ratio2.572.85
EV / EBITDA28.34N/A
FCF yield4.64%N/A

Profitability

MetricVCYTXENE
Gross margin72.09%66.09%
Operating margin17.03%-4974.27%
Net margin20.37%-4612.13%
ROE8.25%-32.94%
ROIC6.72%-35.27%

Growth (annualized)

MetricVCYTXENE
Revenue CAGR (5Y)28.98%N/A
Total return CAGR (5Y)1.45%4.61%

Frequently asked

Is VCYT or XENE more profitable?
VCYT runs the higher net margin — VCYT at 20.37% versus XENE at -4612.13%.
How have VCYT and XENE total returns compared?
Over the past 10 years, VCYT delivered 19.91% and XENE delivered 17.07% annualized total return. Past performance doesn't predict future results.

Go deeper

Full VCYT analysisFull XENE analysisInteractive comparison tool

Dig into the metrics

Veracyte P/E ratioVeracyte ROEXenon Pharmaceuticals ROEVeracyte operating marginXenon Pharmaceuticals operating marginVeracyte revenue growthXenon Pharmaceuticals revenue growthVeracyte free cash flowXenon Pharmaceuticals free cash flow

Veracyte & Xenon Pharmaceuticals appear in these rankings

Fastest Revenue Growth StocksHighest FCF Yield StocksHighest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.